AZ-3102: Protocol AZA-001-31-02: An open-label, single-dose phase 1 study to evaluate the Absorption, Metabolism, and Excretion of [14C]-AZ-3102 in Healthy Male Subjects

This study is an early-stage research project, often called a 'Phase 1' study. It's a very important first step when developing new medicines. The main goal here is to learn about a new medicine called AZ-3102, which is being investigated for a group of rare, inherited conditions known as glycosphingolipid lysosomal storage disorders. These conditions happen when the body can't properly break down certain fatty substances, which then build up and can cause health problems.

In this study, researchers want to see precisely what happens to AZ-3102 once a person takes it. They will be looking at how quickly and how much of the medicine gets into the bloodstream (this is called absorption), how the body changes the medicine (metabolism), and how the body gets rid of it (excretion). To help them track this, a special, very low-level radioactive marker (called [14C]) is added to the medicine, but it's completely safe and does not cause harm.

Gathering this information is essential because it helps scientists understand the right amount of medicine to give and how often to give it in future studies. It also helps to see if there are any immediate safety concerns. This particular study involves healthy men, as it’s often the first step to understand basic drug behaviour before testing it in patients who have the condition. The overall aim is to pave the way for developing a potential new treatment for these challenging disorders.